(CercleFinance.com) – Roche announces Brussels approval of Tecentriq as an adjuvant therapy for a subset of people with early-stage non-small cell lung cancer (NSCLC), its sixth cancer indication lung in Europe.
This approval is for treatment, after complete resection and platinum-based chemotherapy, of adults with NSCLC at high risk of recurrence whose tumors express PD-L1≥50% and who do not have an EGF R mutant or NSCLC ALK-positive.
‘In the Phase III IMpower010 trial, the adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resection stage II-III NSCLC, compared to compared to the best supportive care,” Roche points out.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
